European Primary Care Cardiovascular Society

SGLT2i provides nephroprotective effects in CKD patients

3' education - Sep. 16, 2020 - Prof. Hiddo Heerspink, PhD - Groningen, The Netherlands

Educational information

This video was recorded during the ESC Congress 2020.


Prof. Hiddo Heerspink, PhD is a clinical pharmacologist at the University Medical Center Groningen (UMCG) in the Netherlands


The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of EPCCS.

Read our summary of the DAPA-CKD trial

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: